Related Topics:
Penicillamine
Penicillamine is a pharmaceutical of the chelator class. It is sold under the trade names of Cuprimine and Depen. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). It is a metabolite of penicillin, although it has no antibiotic properties.
Uses
Penicillamine is used as a form of
immunosuppression to treat
rheumatoid arthritis. It works by reducing numbers of
T-lymphocytes, inhibiting
macrophage function, decreasing
IL-1, decreasing
rheumatoid factor, and preventing
collagen from cross-linking.
It is used as a chelating agent:
- In Wilson's disease, a rare genetic disorder of copper metabolism, penicillamine treatment relies on its binding to accumulated copper and elimination through urine.
- In cystinuria, a hereditary disorder featuring increased cystine excretion, penicillamine binds with the cystine to make it more soluble.
History
Dr John Walshe (1956) first described the use of penicillamine in Wilson's disease. He had discovered the compound in the urine of patients (including himself) who had taken
penicillin, and experimentally confirmed that it increased urinary copper excretion by
chelation. He had initial difficulty convincing several world experts of the time (Drs Denny Brown and Cumings) of its efficacy, as they held that Wilson's disease was not primarily a problem of copper homeostasis but of amino acid metabolism, and that
dimercaprol should be used as a chelator. Later studies confirmed both the copper-centered theory and the efficacy of
D-penicillamine. Walshe also pioneered other chelators in Wilson's such as
triethylene tetramine 2HCl and
tetrathiomolybdate (Walshe 2003).
References
- Walshe JM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med. 1956;21:487-95. PMID 13362281.
- Walshe JM. The story of penicillamine: a difficult birth. Mov Disord 2003;18:853-9. PMID 12889074.
External links
Immunosuppressive agents | Chelating agents